ID   HOK-16B-BaP
AC   CVCL_B406
DR   Wikidata; Q54890136
RX   PubMed=1330348;
RX   PubMed=7784058;
RX   PubMed=10675494;
CC   Transformant: ChEBI; CHEBI_29865; Benzo[a]pyrene.
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Derived from site: In situ; Oral cavity; UBERON=UBERON_0000167.
CC   Cell type: Keratinocyte; CL=CL_0000312.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B405 ! HOK-16B
SX   Male
AG   Age unspecified
CA   Transformed cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 12
//
RX   PubMed=1330348; DOI=10.1093/carcin/13.11.1981;
RA   Li S.-L., Kim M.S., Cherrick H.M., Doniger J., Park N.-H.;
RT   "Sequential combined tumorigenic effect of HPV-16 and chemical
RT   carcinogens.";
RL   Carcinogenesis 13:1981-1987(1992).
//
RX   PubMed=7784058;
RA   Park N.-H., Gujuluva C.N., Baek J.-H., Cherrick H.M., Shin K.-H.,
RA   Min B.-M.;
RT   "Combined oral carcinogenicity of HPV-16 and benzo(a)pyrene: an in
RT   vitro multistep carcinogenesis model.";
RL   Oncogene 10:2145-2153(1995).
//
RX   PubMed=10675494; DOI=10.3892/ijo.16.3.591;
RA   Itakura M., Mori S., Park N.-H., Bonavida B.;
RT   "Both HPV and carcinogen contribute to the development of resistance
RT   to apoptosis during oral carcinogenesis.";
RL   Int. J. Oncol. 16:591-597(2000).
//